MedPath

Tenofovir alafenamide

Generic Name
Tenofovir alafenamide
Brand Names
Biktarvy, Descovy, Genvoya, Odefsey, Vemlidy
Drug Type
Small Molecule
Chemical Formula
C21H29N6O5P
CAS Number
379270-37-8
Unique Ingredient Identifier
EL9943AG5J
Background

Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion. Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil. Tenofovir alafenamide is indicated to treat chronic hepatitis B, treat HIV-1, and prevent HIV-1 infections.

Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.

Indication

Tenofovir alafenamide is indicated for the treatment of hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.

In combination with emtricitabine and other antiretrovirals, it is indicated for the treatment of HIV-1 infection in adolescent and adult patients with a weight higher than 35 kg. This combination is also indicated to prevent HIV-1 infections in high risk adolescent and adult patients, excluding patients at risk from receptive vaginal sex. When combined with antiretrovirals other than protease inhibitors that require a CYP3A inhibitor, it can be used to treat pediatric patients weighing 25-35 kg.

In the combination product with emtricitabine and bictegravir, tenofovir alafenamide is considered a complete treatment regimen for HIV-1 infections for treatment-naive patients or patients virologically suppressed for at least three months with no history of treatment failure.

Additionally, the combination product including elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide and the combination product including emtricitabine, rilpivirine and tenofovir alafenamide can be used in the treatment of HIV-1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failure.

The combination product including darunavir, cobicistat, emtricitabine, and tenofovir alafenamide is indicated for the treatment of HIV-1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovir.

Associated Conditions
Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Pre-Exposure Prophylaxis (PrEP)
Clinical Trials
Related News

US Orphan Drug Market Set to Exceed $190 Billion by 2030 as FDA Designations Accelerate

• The US orphan drug market is projected to surpass $190 billion by 2030, with over 7,300 molecules receiving FDA Orphan Drug Designation to date, of which approximately 17.9% have gained approval. • Since 2020, more than half of all new drug approvals by the FDA's Center for Drug Evaluation and Research have been granted orphan status, highlighting the growing importance of rare disease treatments in pharmaceutical development. • Despite criticism over high pricing, exemplified by Abeona Therapeutics' Zevaskyn at $3.1 million per treatment, the orphan drug model has evolved into a sound business strategy offering fewer competitors, faster approvals, and seven-year market exclusivity.

Trump's Executive Order Delays Medicare Drug Price Negotiations, Sparking Industry and Policy Debate

• President Trump signed an executive order extending the exemption period for small-molecule drugs from Medicare price negotiations by four years, a move criticized by advocacy groups as favoring pharmaceutical industry interests. • The order aims to address what the administration calls the "pill penalty" - the current policy where small-molecule drugs (90% of medications) face negotiations after 9 years while biologics have longer exemption periods. • The Medicare Drug Price Negotiation Program, established under the Biden administration, had already achieved price reductions of 38-79% on 10 high-cost drugs with projected savings of $6 billion if applied in 2023.

2025 Pharmaceutical Pipeline: Major Patent Expirations Set to Transform Drug Market with Generics and Biosimilars

• The US pharmaceutical market is poised for significant change in 2025 as several blockbuster drugs including Xarelto, Entresto, and Stelara face patent expirations, opening the door to generic and biosimilar competition. • Multiple biosimilars for ustekinumab (Stelara) are entering the market in 2025, with Wezlana already launched in January as the first interchangeable biosimilar, while other major drugs like ticagrelor and denosumab will also face competition. • The pharmaceutical pipeline continues to expand with innovative therapies for cancer and neurological disorders, alongside the Medicare Drug Price Negotiation program which will further impact pricing dynamics for high-cost medications.

Lenacapavir and Broadly Neutralizing Antibodies Show Promise as Twice-Yearly HIV Treatment

• Phase II trial results demonstrate that lenacapavir combined with two broadly neutralizing antibodies (teropavimab and zinlirvimab) maintained viral suppression in 96% of participants over 26 weeks, comparable to daily oral regimens. • The LTZ regimen (lenacapavir, teropavimab, zinlirvimab) could become the first complete twice-yearly HIV treatment option, potentially transforming care for people living with HIV by eliminating daily pill requirements. • Pre-treatment screening for viral sensitivity to the antibodies is crucial, with approximately half of those screened showing high susceptibility to both antibodies, while others demonstrated sensitivity to at least one.

ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025

• Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention. • Long-term follow-up data from multiple studies confirms the sustained efficacy and safety of Cabenuva (cabotegravir + rilpivirine LA) as a complete treatment regimen for people living with HIV. • Late-breaking phase IIb data reveals promising results for an investigational broadly neutralizing antibody (VH3810109) in combination with cabotegravir LA, potentially expanding long-acting treatment options.

Gilead Sciences Resolves Major Patent Disputes with $1.25B Settlement to ViiV and Agreement with US Government

• Gilead Sciences has settled a significant patent dispute with ViiV Healthcare, agreeing to pay $1.25 billion plus ongoing royalties on Biktarvy sales until 2027, resolving litigation dating back to 2018. • Separately, Gilead reached a settlement with the US government over patent infringement allegations related to HIV prevention drugs Truvada and Descovy, following Gilead's victory in a 2023 jury trial. • Despite these legal resolutions, Gilead reported a 2% decline in fourth quarter sales, primarily due to decreased demand for COVID-19 therapy Veklury, while HIV treatment Biktarvy remained strong with 22% growth.

Pharmaceutical Industry Braces for $236 Billion Patent Cliff by 2030: Strategic Responses from Major Players

• The global pharmaceutical industry faces a $236 billion patent cliff between 2025-2030, with nearly 70 blockbuster drugs losing exclusivity and exposing major companies to significant revenue losses. • Key drugs approaching patent expiration include Merck's Keytruda ($25B), Bristol-Myers Squibb's Eliquis ($12B), and Johnson & Johnson's Stelara ($10.9B), forcing companies to rapidly adapt through pipeline diversification and cost-cutting measures. • Companies are responding with increased M&A activity, AI-driven R&D efficiency, and strategic pivots to high-growth therapeutic areas, while the cliff will likely improve drug affordability but potentially slow innovation.

Promising Phase III Results for Once-a-Month HIV Treatment

Janssen and ViiV Healthcare have reported positive phase III trial results for their once-monthly injectable HIV treatment, combining cabotegravir and Edurant. This innovative regimen could significantly reduce the treatment burden from daily pills to just 12 injections per year, with comparable efficacy to current oral therapies. The findings, presented at the Conference on Retroviruses and Opportunistic Infections, highlight a potential paradigm shift in HIV treatment.

Sarepta Seeks Accelerated Approval for DMD Gene Therapy SRP-9001

• Sarepta Therapeutics has submitted SRP-9001 (delandistrogene moxeparvovec) to the FDA for accelerated approval to treat ambulatory Duchenne muscular dystrophy (DMD) patients. • The filing is based on positive data from early-stage studies, showing improvements in clinical function and a consistent safety profile, while awaiting Phase 3 EMBARK results. • SRP-9001, a one-time gene therapy, delivers a shortened dystrophin gene via an AAV vector, addressing the underlying genetic defect in DMD patients. • If approved, SRP-9001 would offer a one-time treatment option for DMD, contrasting with Sarepta's existing chronic exon-skipping therapies.

Merck's Doravirine/Islatravir Combo Shows Promise in Phase 3 HIV-1 Trials

• Merck's doravirine/islatravir (DOR/ISL) regimen demonstrated non-inferiority compared to current antiretroviral therapies in Phase 3 trials for HIV-1. • The DOR/ISL combination met primary efficacy endpoints, maintaining viral suppression in adults with virologically suppressed HIV-1 infection. • Merck plans to submit detailed findings from these trials to regulatory authorities for review and potential approval. • The ongoing Phase 3 trials are also evaluating DOR/ISL in treatment-naïve individuals, expanding its potential application.

Lenacapavir: Twice-Yearly Injection Shows High Efficacy in HIV Prevention

• Lenacapavir, administered as a twice-yearly injection, demonstrates a 96% reduction in HIV infection risk compared to background incidence. • Clinical trials reveal lenacapavir's superior efficacy over daily oral PrEP medications like Truvada, particularly addressing adherence challenges. • The FDA is reviewing lenacapavir for potential approval in 2025, offering a promising long-acting option for HIV prevention. • Global health experts emphasize the importance of equitable access and affordability to ensure widespread adoption of lenacapavir.

FDA Accepts Gilead's Lenacapavir for HIV Prevention with Priority Review

• The FDA has accepted Gilead's NDA for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP). • Lenacapavir demonstrated 100% risk reduction in cisgender women and 96% risk reduction in a diverse population, compared to background HIV incidence. • The FDA has granted priority review with a target action date of June 19, 2025, potentially making it the first twice-yearly HIV prevention option. • Gilead is also pursuing global access, including submissions to the EMA and voluntary licensing agreements to facilitate availability in low- and middle-income countries.

Gilead's Lenacapavir Shows Promise in HIV Prevention and Treatment

• Gilead's twice-yearly injectable lenacapavir reduced HIV infections by 96% in a Phase 3 trial, demonstrating superiority to daily oral Truvada for PrEP. • The PURPOSE 2 trial included cisgender men, transgender individuals, and gender non-binary people, showing broad efficacy across diverse populations. • Gilead plans to begin regulatory filings for lenacapavir for PrEP by the end of 2024, with potential launch in 2025, prioritizing access in high-incidence, resource-limited countries. • A Phase 2 trial of once-weekly oral islatravir and lenacapavir maintained viral suppression in adults with HIV, paving the way for Phase 3 trials.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy